First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer GroupMarinde J. G. Bond, Johanneke H.M.J.V. Vestjens, Karen Bolhuis et al.|The Lancet Oncology|2023Cited by 168
Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trialSusan van der Lei, Karin Nielsen, Koert de Jong et al.|The Lancet Oncology|2025Cited by 138
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)Koen P. Rovers, Aeilko H. Zwinderman, Checca Bakkers et al.|BMC Cancer|2019Cited by 111
Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial GroupSanne Nieuwenhuizen, Hester J. Scheffer, Robbert S. Puijk et al.|Cancers|2020Cited by 109
Modern Treatment of Rectal Cancer Closes the Gap Between Common Adenocarcinoma and Mucinous CarcinomaNiek Hugen, Irıs D. Nagtegaal, Cornelis JH van de Velde et al.|Annals of Surgical Oncology|2015Cited by 64